Black Diamond Therapeutics reported a net income of $37.48 million for the nine‑month period ended September 30 2025, reversing a $53.69 million loss for the same period in 2024. The company’s full‑year 2025 net income reached $22.4 million, compared with a $69.7 million loss in 2024. In the fourth quarter alone, Black Diamond posted a net loss of $15.1 million, or $0.27 per share, missing the consensus estimate of $0.18 per share.
Full‑year 2025 research and development expenses fell to $33.6 million from $51.3 million in 2024, a decline of 34 percent, while general and administrative costs dropped to $16.6 million from $27.5 million, a 39 percent reduction. The cost savings were driven by the out‑licensing of the BDTX‑4933 RAF inhibitor to Servier, which eliminated a secondary program, and by a restructuring announced in October 2024 that streamlined operations and reduced workforce costs.
Cash and cash equivalents stood at $128.7 million as of December 31 2025, a figure that extends the company’s runway into the second half of 2028 or Q4 2027, depending on future funding. The Servier licensing agreement, signed in March 2025, provided an upfront payment of $70 million and the potential for up to $710 million in milestone payments and royalties, providing a significant financial cushion and freeing capital to focus on the lead asset, silevertinib.
Clinical data from the ongoing Phase 2 study of silevertinib in newly diagnosed EGFR‑mutant non‑small cell lung cancer were highlighted, showing a 60 percent objective response rate, an 86 percent central nervous system response rate, and a 91 percent disease‑control rate as of a November 3 2025 data cutoff. These results reinforce the drug’s potential to address an unmet need in both lung and brain tumors.
Mark Velleca, President and CEO, said, “We continue to focus on advancing silevertinib for the treatment of patients with EGFR‑mutant NSCLC and EGFR‑altered GBM.” He added, “We are looking forward to sharing a clinical update later this quarter from our silevertinib Phase 2 trial in newly diagnosed patients with EGFR‑mutant NSCLC. The update will include ORR and preliminary duration of treatment data, while PFS data is expected in the first half of 2026.”
Analysts had expected a fourth‑quarter EPS of $0.18 per share; the reported $0.27 loss represents a miss of $0.09 per share. The miss reflects the company’s continued investment in clinical development and the impact of the Servier deal on cash flow, while the overall positive full‑year earnings demonstrate the effectiveness of the cost‑control measures and the strengthening of the company’s financial position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.